CTOs on the Move


 
Founded in 2013, Aphria is integrating their growing expertise with Health Canada`s new Access to Cannabis for Medical Purposes Regulations (ACMPR) for the medicinal marijuana industry. Possessing greenhouse related growing experience in plant and produce related expertise since 1943, Aphria is positioned to be an industry leader in providing patients with the highest quality medical marijuana. Aphria has developed integrated greenhouse growing solutions specifically focused on quality production of cannabis. With the authorization of quantity scale marijuana growing, Aphria greenhouse operations are a natural fit. Aphria is a licensed producer of Medicinal Marijuana under the Health Canada Regulations. Grown in ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.aphria.com
  • 35 McCaul St. Suite 201
    Toronto, ON CAN M5T 1V7
  • Phone: 833.254.4877

Executives

Name Title Contact Details

Funding

Aphria raised $80M on 12/02/2019

Similar Companies

Intellipharmaceutics

We believe that our Hypermatrix technology is a novel and robust controlled-release drug delivery platform. This unique technology allows us to provide life-cycle management or new chemical entity delivery system solutions for virtually any small molecule. The flexibility of this technology allows us to quickly develop complex drug delivery solutions.

Southwood Healthcare

Southwood Healthcare is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Falks Woodland Pharmacy

Falks Woodland Pharmacy, Inc. is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sertech

Sertech is a Batavia, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jaguar Animal Health

Jaguar Animal Health is a company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Our products are designed with a thorough understanding of not only species-specific health issues, but also market practices, the economics of current treatment strategies, competitive dynamics, government initiatives, such as concern for extensive antibiotic usage, and effective channels for new product introductions. In addition to Canalevia™ for dogs and Neonorm™ for preweaned dairy calves, we are developing formulations of these products across multiple animal species and market channels. Our management team has significant experience in gastrointestinal and animal health product development. This experience includes the development of crofelemer for human use, from discovery and preclinical and clinical toxicity studies, including the existing animal studies to be used for Canalevia™ regulatory approvals, through human clinical development. Our team also includes individuals who have prior animal health experience at major pharmaceutical companies, including Ciba-Geigy Corp., now Novartis International AG, SmithKline Beecham Corporation, now GlaxoSmithKline LLC, and the animal health group of Pfizer Inc., now Zoetis Inc.